Depletion of USP15 causes decreased cell viability of ovarian cancer cells expressing the p53-R175H mutant protein, suggesting that targeting USP15 in p53-R175H mutant-containing tumors would facilitate the inhibition of oncogenic mutant p53 and enhance cancer immunotherapy [81]. Here, TP53 is linked to ovarian cancer.